Research programme: G protein-coupled receptor modulators - EPIX/GlaxoSmithKline

Drug Profile

Research programme: G protein-coupled receptor modulators - EPIX/GlaxoSmithKline

Alternative Names: GPCR modulators - EPIX/GlaxoSmithKline; GPCR-targeted therapeutics - EPIX/GlaxoSmithKline

Latest Information Update: 16 Oct 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EPIX Pharmaceuticals
  • Class
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued CNS disorders

Most Recent Events

  • 05 Jun 2008 EPIX Pharmaceuticals achieves milestone by identifying three lead candidates for optimisation in the third GPCR discovery programme in collaboration with GlaxoSmithKline
  • 06 Nov 2007 EPIX Pharmaceuticals achieves milestone by identifying three lead candidates for optimisation in the second GPCR discovery programme in collaboration with GlaxoSmithKline
  • 15 Aug 2007 EPIX achieves milestone by identifying three lead candidates for optimisation in the first GPCR discovery programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top